March 28, 2023
RegMed Investors’ (RMi) pre-open: the market and sector turmoil ain’t over
March 27, 2023
RegMed Investors’ (RMi) pre-open: no bad bank news will be good news as Q1/23 will come to a close this week
March 24, 2023
RegMed Investors’ (RMi) pre-open: good news, it’s Friday
March 23, 2023
RegMed Investors’ (RMi) pre-open: Bottom, bottom is it in sight?
March 22, 2023
RegMed Investors’ (RMi) pre-open: What’s on tap?
March 21, 2023
RegMed Investors’ (RMi) pre-open: what’s the range of price movements?
March 20, 2023
RegMed Investors’ (RMi) pre-open: still vulnerable and receptive to electronic trading nibbles and bites
March 17, 2023
RegMed Investors’ (RMi) pre-open: a quadruple-witching Friday
March 16, 2023
RegMed Investors’ (RMi) pre-open: will there be another Black Swan event for the cell and gene therapy sector and how soon versus when?
March 15, 2023
RegMed Investors’ (RMi) pre-open: money’s leaving share pricing due to inherent risks
March 14, 2023
RegMed Investors’ (RMi) pre-open: from the fear of the SVB scenario came
March 10, 2023
RegMed Investors’ (RMi) pre-open: probably more down but, almost ready to start buying bottoms
March 9, 2023
RegMed Investors’ (RMi) pre-open: sector extends the slide while oversold seek value recognition
March 8, 2023
RegMed Investors’ (RMi) pre-open: just when you thought
March 7, 2023
RegMed Investors’ (RMi) pre-open: waiting to hang on Jerome’s policy message
March 6, 2023
RegMed Investors’ (RMi) pre-open: buy on downslide, sell into the upswing
March 3, 2023
RegMed Investors’ (RMi) pre-open: a test of strength versus weakness
March 2, 2023
RegMed Investors’ (RMi) pre-open: sector swings back and forth although I basically remain picking short-term indications
March 1, 2023
RegMed Investors’ (RMi) pre-open: don’t walk when the direction signs are flashing
February 28, 2023
RegMed Investors’ (RMi) pre-open: peaking while seeking acquiescence or validation
February 22, 2023
RegMed Investors’ (RMi) pre-open: pick-up a few of the oversold while we wait again for Jerome’s minutes
February 21, 2023
RegMed Investors’ (RMi) pre-open: after a holiday and week of wupp’in
February 17, 2023
RegMed Investors’ (RMi) pre-open: sector earning’s season reporting begins as volatility continues
February 16, 2023
RegMed Investors’ (RMi) pre-open: does the cell/gene therapy sector have legs with a new consignment of economic data?
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2023 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.